FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291186561> ?p ?o ?g. }

• W4291186561 endingPage "54" @default.
• W4291186561 startingPage "54.1" @default.
• W4291186561 abstract "Background Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that belongs to a class of targets devoid of catalytic function, thus deemed “undruggable” by standard modalities such as small molecule inhibitors or biologics. STAT3 can be activated by various receptor- and non-receptor tyrosine kinases, playing a critical role in activation pathways triggered by cytokines, hormones, and growth factors, making it an attractive target for the treatment of inflammatory diseases. Objectives Kymera has developed heterobifunctional molecules that selectively target STAT3 for degradation and elimination by the ubiquitin-proteasome pathway. We sought to evaluate the pharmacologic potential of these STAT3 degraders through in vitro and in vivo studies relevant to human autoimmune disease, including murine collagen-induced arthritis. Methods We evaluated the impact of STAT3 degraders on the activation of human monocytes, dermal fibroblasts, CD4+ T cells, and PBMC by LPS, IL-6/IL-6R, IL-21, IL-23, as well as anti-CD3/CD28 plus a cocktail of cytokines and antibodies. STAT3 degradation and pSTAT3 inhibition were determined in comparison to a JAK1/2 small molecule inhibitor. Inhibition of cytokines, chemokines, and collagen release, as well as Th17 (CD4+CD25-RORγt+CXCR6+) and Treg (CD4+CD25+CD127lowFOXP3+) expansion were used as in vitro efficacy assays. Finally, STAT3 degraders were tested in vivo, in a mechanistic (IL-6 challenge) as well as a disease model (murine CIA) relevant to rheumatology indications. Results STAT3 degraders showed broad and potent activity in-vitro against TLR receptor and cytokine-induced activation of immune and stromal cells, including soluble mediator release such as MCP-1/CCL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner superior to JAK1/2 inhibition. In mice injected with IL-6, plasma levels of serum amyloid A were dose-dependently suppressed by STAT3 degradation. In the murine collagen-induced arthritis model, STAT3 degradation resulted in robust, dose-dependent delay of disease onset and decreased disease incidence, clinical scores, local cytokine expression (paws) and histopathological scores, including the complete alleviation of periosteal bone growth. Conclusion These data demonstrate the broad activity of STAT3 degradation in alleviating autoimmune inflammation in models relevant to human disease. Targeted protein degradation of STAT3 thus represents a novel therapeutic approach to treating autoimmune/autoinflammatory diseases such as rheumatoid arthritis. Disclosure of Interests Cedric Hubeau Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Jeffrey Sullivan Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Crystal Brown Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Michele Mayo Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Vaishali Dixit Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Bradley Enerson Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Haojing Rong Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Bin Yang Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Chris De Savi Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Jared Gollob Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Nello Mainolfi Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics, Anthony Slavin Shareholder of: Kymera Therapeutics, Employee of: Kymera Therapeutics." @default.
• W4291186561 created "2022-08-13" @default.
• W4291186561 creator A5001447321 @default.
• W4291186561 creator A5013644527 @default.
• W4291186561 creator A5013703469 @default.
• W4291186561 creator A5020386122 @default.
• W4291186561 creator A5030738169 @default.
• W4291186561 creator A5031269852 @default.
• W4291186561 creator A5044783278 @default.
• W4291186561 creator A5045346440 @default.
• W4291186561 creator A5055474785 @default.
• W4291186561 creator A5071728480 @default.
• W4291186561 creator A5084283975 @default.
• W4291186561 creator A5086486689 @default.
• W4291186561 date "2022-05-23" @default.
• W4291186561 modified "2023-09-23" @default.
• W4291186561 title "OP0080 STAT3 DEGRADERS INHIBIT Th17 DEVELOPMENT AND CYTOKINE PRODUCTION RESULTING IN PROFOUND INHIBITION OF COLLAGEN-INDUCED AUTOIMMUNE MURINE ARTHRITIS" @default.
• W4291186561 doi "https://doi.org/10.1136/annrheumdis-2022-eular.2068" @default.
• W4291186561 hasPublicationYear "2022" @default.
• W4291186561 type Work @default.
• W4291186561 citedByCount "0" @default.
• W4291186561 crossrefType "journal-article" @default.
• W4291186561 hasAuthorship W4291186561A5001447321 @default.
• W4291186561 hasAuthorship W4291186561A5013644527 @default.
• W4291186561 hasAuthorship W4291186561A5013703469 @default.
• W4291186561 hasAuthorship W4291186561A5020386122 @default.
• W4291186561 hasAuthorship W4291186561A5030738169 @default.
• W4291186561 hasAuthorship W4291186561A5031269852 @default.
• W4291186561 hasAuthorship W4291186561A5044783278 @default.
• W4291186561 hasAuthorship W4291186561A5045346440 @default.
• W4291186561 hasAuthorship W4291186561A5055474785 @default.
• W4291186561 hasAuthorship W4291186561A5071728480 @default.
• W4291186561 hasAuthorship W4291186561A5084283975 @default.
• W4291186561 hasAuthorship W4291186561A5086486689 @default.
• W4291186561 hasBestOaLocation W42911865611 @default.
• W4291186561 hasConcept C171958077 @default.
• W4291186561 hasConcept C203014093 @default.
• W4291186561 hasConcept C2777077863 @default.
• W4291186561 hasConcept C2778690821 @default.
• W4291186561 hasConcept C2778923194 @default.
• W4291186561 hasConcept C502942594 @default.
• W4291186561 hasConcept C62478195 @default.
• W4291186561 hasConcept C71924100 @default.
• W4291186561 hasConcept C86803240 @default.
• W4291186561 hasConcept C95444343 @default.
• W4291186561 hasConceptScore W4291186561C171958077 @default.
• W4291186561 hasConceptScore W4291186561C203014093 @default.
• W4291186561 hasConceptScore W4291186561C2777077863 @default.
• W4291186561 hasConceptScore W4291186561C2778690821 @default.
• W4291186561 hasConceptScore W4291186561C2778923194 @default.
• W4291186561 hasConceptScore W4291186561C502942594 @default.
• W4291186561 hasConceptScore W4291186561C62478195 @default.
• W4291186561 hasConceptScore W4291186561C71924100 @default.
• W4291186561 hasConceptScore W4291186561C86803240 @default.
• W4291186561 hasConceptScore W4291186561C95444343 @default.
• W4291186561 hasIssue "Suppl 1" @default.
• W4291186561 hasLocation W42911865611 @default.
• W4291186561 hasOpenAccess W4291186561 @default.
• W4291186561 hasPrimaryLocation W42911865611 @default.
• W4291186561 hasRelatedWork W1804193440 @default.
• W4291186561 hasRelatedWork W2053257742 @default.
• W4291186561 hasRelatedWork W2094500359 @default.
• W4291186561 hasRelatedWork W2154799225 @default.
• W4291186561 hasRelatedWork W2744886175 @default.
• W4291186561 hasRelatedWork W2972231100 @default.
• W4291186561 hasRelatedWork W3032419375 @default.
• W4291186561 hasRelatedWork W3163444955 @default.
• W4291186561 hasRelatedWork W4303628910 @default.
• W4291186561 hasRelatedWork W2019984361 @default.
• W4291186561 hasVolume "81" @default.
• W4291186561 isParatext "false" @default.
• W4291186561 isRetracted "false" @default.
• W4291186561 workType "article" @default.